Analysts Upgrade Vertex Pharmaceuticals as Biotech Sector Recovers
Bernstein upgraded Vertex Pharmaceuticals to Outperform, naming it a top 2026 biotech pick. UBS also initiated coverage with a Buy rating, citing an attractive risk/reward profile ahead of key data readouts.